Department of Internal Medicine III, Klinikum der Universität München, Munich, Germany; Clinical Co-Operation Group Immunotherapy at the Helmholtz Institute Munich, Munich, Germany; Division of Clinical Pharmacology, Department of Internal Medicine IV, Klinikum der Universität München, Munich, Germany.
Department of Internal Medicine III, Klinikum der Universität München, Munich, Germany; Clinical Co-Operation Group Immunotherapy at the Helmholtz Institute Munich, Munich, Germany.
Leuk Res. 2014 Aug;38(8):964-9. doi: 10.1016/j.leukres.2014.05.014. Epub 2014 Jun 2.
Cyclic cytotoxic maintenance therapy can be applied to patients with AML in post-remission. We studied the immune status of AML patients in complete remission and the effect of maintenance therapy on different immune cell populations. Patients in complete remission had reduced NK, TH and Treg counts and a reduced NK activation capacity. In the course of cytotoxic maintenance therapy, NK counts further declined, while TH and Treg cells increased, with lower proliferative potential of TH cells. We conclude that immunotherapeutic approaches in post-remission have to consider reduced NK cell function and further impairment of cellular immune responses during cytotoxic therapy.
周期性细胞毒维持治疗可应用于缓解后 AML 患者。我们研究了完全缓解 AML 患者的免疫状态和维持治疗对不同免疫细胞群的影响。完全缓解的患者 NK、TH 和 Treg 计数减少，NK 激活能力降低。在细胞毒维持治疗过程中，NK 计数进一步下降，而 TH 和 Treg 细胞增加，TH 细胞的增殖潜力降低。我们的结论是，缓解后免疫治疗方法必须考虑 NK 细胞功能降低和细胞毒治疗期间细胞免疫反应的进一步受损。
